Hepatoprotective and antioxidant activities of extracts from Salvia—Nelumbinis naturalis against nonalcoholic steatohepatitis induced by methionine- and choline-deficient diet in mice
© Liu et al.; licensee BioMed Central Ltd. 2014
Received: 13 August 2014
Accepted: 28 October 2014
Published: 19 November 2014
Nonalcoholic steatohepatitis (NASH), the advanced stage of nonalcoholic fatty liver disease that is characterized by both steatosis and severe injury in liver, still lacks efficient treatment. The traditional Chinese formula Salvia—Nelumbinis naturalis (SNN) is effectively applied to improve the symptoms of nonalcoholic simple fatty liver (NAFL) patients. Previous studies have confirmed that SNN could reduce the liver lipid deposition and serum transaminases of NAFL experimental models. This study aims to determine whether SNN is effective for murine NASH model and investigate the underlying pharmacological mechanisms.
C57BL/6 J mice were fed with methionine- and choline-deficient (MCD) diet for six weeks to induce NASH. Simultaneously, SNN or saline was intragastrically administered daily to the mice in the SNN or model group, respectively. A standard diet was given to the control mice. Serum biochemical indices and tumor necrosis factor-α were measured. Liver histopathology was observed, and the contents of triglycerides and lipid peroxide malondialdehyde (MDA) in liver homogenates were evaluated. The hepatic expression and/or activation of genes associated with inflammation, apoptosis, and oxidative stress were determined by quantitative RT-PCR or Western blot analysis.
The prominent liver steatosis displayed in the NASH model was prevented by SNN. The liver injury of NASH mice was obviously manifested by the increased levels of serum transaminases and bilirubin, as well as the lobular inflammation, elevated pro-inflammatory cytokines, and upregulated apoptosis in liver tissues. SNN administration improved the aforementioned pathological changes. The increased hepatic levels of MDA and cytochrome P450 2E1 of the model confirmed the unregulated balance of oxidative stress. The hepatic expression of nuclear factor erythroid 2-related factor 2 and its target genes decreased, whereas c-Jun N-terminal kinase activation in the model mice increased. Treating the mice with SNN significantly improved oxidative stress-related harmful factors.
This study shows that SNN can protect the liver from severe steatosis and damage induced by MCD diet, which suggests the potential use of SNN on the treatment of NASH patient. The results also indicate that improving the hepatic antioxidant capability of the liver may contribute to the underlying hepatoprotective mechanism.
KeywordsSalvia—Nelumbinis naturalis NASH Liver injury Oxidative stress
Nonalcoholic fatty liver disease (NAFLD) is an increasing prevalent health problem that ranges from simple fatty infiltration of the liver parenchyma (nonalcoholic simple fatty liver, NAFL) to steatosis with inflammation and hepatocellular ballooning (nonalcoholic steatohepatitis, NASH) and ultimately cirrhosis . Patients with NAFL appear to have a nonprogressive course with benign prognosis. However, approximately 10% to 30% of NAFL patients develop NASH with more serious form of liver damage, which may further progress to cirrhosis in as many as 25% of the cases and suffer from its complications, including portal hypertension, liver failure and hepatocellular carcinoma .
NAFLD begins with an aberrant lipid accumulation in the liver , followed by initial changes that induce the liver to be sensitive to oxidative stress (OS) and pro-inflammatory cytokines . OS is an etiological factor in many acute and chronic liver diseases and plays a critical role in the progression of NAFL to NASH . Sources of OS include elevated level of cytochrome P450 2E1 (CYP2E1), lipid peroxidation, and cytokine induction ,. CYP2E1 is an inducible enzyme hydroxylating fatty acid that can initiate lipid peroxidation process ,. CYP2E1 is frequently induced in NASH, leading to increased reactive oxygen species (ROS) that trigger OS . Considerable OS causes lipid peroxidation of cell membrane and activation of hepatic stellate cell, resulting in inflammation, apoptosis, and fibrogenesis . Increased OS can enhance the secretion of inflammatory cytokines and hepatocyte apoptosis, which possess pivotal roles in the pathogenesis of liver damage in NASH -. Pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), which are involved in liver injury and repair, are also considered as NASH indicators -. TNF-α plays an important role throughout the progression of steatosis to NASH . The effects of TNF-α result in additional lipid peroxidation of mitochondrial membranes, thereby further enhancing OS in NASH . Therefore, inhibiting TNF-α can suppress liver injury in NASH .
Valuable therapeutic interventions against NASH remain limited; hence, searching for a safe and effective drug is relatively essential . Salvia—Nelumbinis naturalis (SNN) formula (initially called Jiang Zhi Granule) is a compound prescription in traditional Chinese medicine composed of five medicinal herbs, namely, Salviae (Danshen in China), Nelumbinis (Heye in China), Herba Gynostemmatis (Jiaogulan in China), Rhizoma Polygoni Cuspidati ( Huzhang in China), and Herba Artemisiae scopariae (Yinchen in China) ,. This complex prescription has been used to treat NAFL in clinical practice in China, with significant effects of alleviating hepatic steatosis with few side effects . In 2008, SNN was granted the permission and certification by the Chinese SFDA (No. 2008 L11181) to be used as drug for clinical trials. SNN can improve the liver to spleen ratio (L/S ratio) and decrease the body mass index of NAFL patients . Previous in vivo studies have also confirmed the effect of SNN on NAFL and partially unraveled its underlying mechanisms, including improving leptin and insulin resistance, inhibiting transcription of liver X receptor α (LXR-α)-mediated sterol regulatory element binding protein-1c (SREBP-1c), and maturation of SREBP-1c independent of LXR-α -. In vitro studies have indicated that the components extracted from SNN reduce lipid droplet deposition and increase the resistance to damage of hepatocytes induced by free fatty acids ,. Taken together, our previous studies mainly focused on the therapeutic function of SNN on simple steatosis. Therefore, in the present study, we tried to determine whether and how SNN is potentially effective for NASH. For this objective, the NASH model of mouse induced by methionine- and choline-deficient (MCD) diet was used, of which the major pathological factors are excess OS and failure of lipid transport from hepatocytes . SNN extract was administered to the NASH model to observe the efficacy and to further investigate the related molecular mechanism of the traditional formula.
Male C57BL/6 J mice weighing 20 g to 25 g were purchased from Shanghai SLAC Laboratory Animal Technology Company (License No. SCXK (HU) 2007–0005). The animals were housed in a standard 12 h light/dark cycle at 22 ± 2°C with 55 ± 10% humidity and had access to food and water. The animal experiments were approved by the Institutional Animal Care and Use Committee of Shanghai University of Traditional Chinese Medicine. All animal procedures were performed in accordance to the guide for the care and use of laboratory animals .
Drug and chemicals
SNN was provided by the Department of Pharmacy of Longhua Hospital, Shanghai, China. This herbal formula was triturated and blended to powder. Subsequently, 20 mg of the powder was extracted with 25 mL of water/methanol (5:95, V/V) in an ultrasonic bath at 42 kHz frequency for 30 min. The chemical profile of SNN has already been analyzed by ultra-performance liquid chromatography . SNN was stored at 4°C and diluted to the desired concentrations in distilled water at the time of administration. Hematoxylin—eosin (HE) solution was purchased from Yixin Biological Technology, Inc. (Shanghai, China), and Oil red O was from Sigma-Aldrich (St. Louis, MO, USA). All reagents were at least of analytic grade and applied according to manufacturer's instructions.
Experimental design of animals
A total of 36 C57BL/6 J mice were adaptively fed for 7 days and were randomly allocated into the following experimental groups (n = 12 per group) according to their body weights: (1) the control mice given a standard control diet, (2) the model mice fed with MCD diet, and (3) mice fed with MCD diet together with oral garvage of SNN (860 mg/kg body weight) once a day. The application dose of SNN was calculated based on the standard dose in clinical practice, previous in vivo experiments, dose conversion among animals and human, and extract yield ,,,. The MCD and control diets were purchased from Research Diets, Inc. (New Brunswick, NJ, USA). At the end of the sixth week, all animals were fasted overnight and sacrificed. The serum was separated for further investigation. Mice livers were weighed and frozen or fixed in 10% formalin.
Serum biochemical analysis
The alanine aminotransferase activity (ALT), aspartate aminotransferase activity (AST), total bilirubin (TBIL), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) were determined to assess liver function using commercially available kits (Jiancheng Institute of Bio Engineering, Inc., Nanjing, China) according to the manufacturer's instructions. The serum concentration of TNF-α was measured by a Bio-Plex assay kit (Bio-Rad, Hercules, USA) with the Bio-Plex 200 system (Bio-Rad).
The liver sections were stained with HE according to the standard methods. In brief, the fresh liver tissue samples were fixed in 10% formalin and embedded in paraffin. The samples were cross-cut into slices of 4 μm to 5 μm and stained with HE staining solution. Finally, the stained sections were observed and photographed under a light microscope (with 200× magnification). All HE stained sections (n = 12) were evaluated in a blinded manner by two pathologists for NAFLD activity score (NAS) including the components of steatosis, inflammation and hepatocyte ballooning. The scoring system was as follows: steatosis grade (0–3; 0: <5%, 1: 5%–33%, 2: 33%–66%, and 3: >66%), lobular inflammation (0–3; 0: no foci, 1: few foci/200×, 2: many foci/200×, and 3: >4 foci/200× scope), and balooning (0-2; 0: no foci, 1: <2 foci/200×, and 2: 2-4 foci/200× .
Oil Red O staining
For Oil Red O staining, a stock solution of Oil Red O (0.5 g/100 mL) in isopropanol was prepared, and protected from light. After being fixed with 10% paraformaldehyde for 30 min, the frozen liver sections with 10 μm thickness were stained with Oil Red O for 60 min. Nonspecific staining was removed with 70% ethanol. The sections were counterstained with hematoxylin diluted at 1:10 and mounted with 80% glycerol. The stained sections were visualized and photographed under a microscope (Olympus IX71, Tokyo, Japan).
Evaluation of lipid content in liver tissues
Exactly 3 ml of Ethanol–acetone (1:1) was added to the hepatic tissues (200 mg), which was then homogenized in an ice bath and mixed thoroughly at 4°C overnight. After 24 h, the liver tissues were centrifuged at 3000 rpm and 4°C for 20 min. Subsequently, the supernatant was transferred to a new tube, and TG was measured based on the instructions on TG assay kit (Jiancheng Institute of Bio Engineering, Inc.) using the colorimetric method.
Measurement of MDA in liver tissues
The contents of malondialdehyde (MDA) in the liver tissues were determined through thiobarbutaric acid (TBA) method using a MDA testing kit (Beyotime Institute of Biotechnology, shanghai, China). Briefly, the liver tissues (200 mg) were homogenized in 0.15 M KCl solution. The homogenate and 10% trichloroacetic acid were mixed (1:1) and centrifuged. The supernatant was suspended into TBA. After placing in a water bath for 15 min, the samples were centrifuged at 1000 g for 15 min. The optical density of the supernatants was measured at 532 nm with a BioTek SynergyH4 enzyme-labeled instrument (USA).
Quantitative reverse transcription polymerase chain reaction (RT-PCR)
The primer sequences for quantitative RT- PCR used in this study
Forward : 5'-GAGACCTTCAACACCCCAGC-3'
Reverse : 5'-ATGTCACGCACGATTTCCC-3'
Forward : 5'-CCCTCCAGAAAAGACACCATG-3'
Reverse : 5'-CACCCCGAAGTTCAGTAGACAG-3'
Forward : 5'-TCGTGCTGTCGGACCCAT-3'
Reverse : 5'-GGCTTGTGCTCTGCTTGTGA-3'
Forward : 5'-AGGCTGTCAAGGAGGTGCTAC-3'
Reverse : 5'-GTTTCCCCATTCCCCAGTC-3'
Forward : 5'-TCTTCCATTTACGGAGACCCA-3'
Reverse : 5'-GATTCACGCATAGGAGCACTG-3'
Forward : 5'-TCAACTGGTTTACAGCATTGGC-3'
Reverse : 5'-GCTTGGAGCAAAATAGAGTGGG-3'
Forward : 5'-ACCCTGCTGTCCCAGAACC-3'
Reverse : 5'-GCGAGCCACATAGGCAGAG-3'
Protein concentration was determined using a BCA protein assay kit (CoWin Bioscience, Beijing, China). The protein sample was resolved by 10% denaturing sodium dodecyl sulfate polyacrylamide gel electrophoresis and was blotted onto Immobilon-P PVDF membranes (Millipore, Billerica, MA, USA). After being blocked by 5% milk, the membrane was incubated with primary antibodies at 4°C overnight. The antibodies against c-Jun N-terminal kinase (JNK), Phospho-JNK, activated Caspase-3, Bcl-2-associated X (Bax) protein, and Bcl-2 were purchased from Cell Signaling Technology (Danvers, MA, USA). The antibody against CYP2E1 was obtained from Abcam (Cambridge, MA, USA), and β-actin was obtained from Huaan Biological Technology (Hangzhou, China). Subsequently, the membrane was incubated in a horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse secondary antibody from Thermo Scientific (Rockford, IL, USA) for 1 h. The signal was visualized by enhanced chemiluminescence HRP substrate (Millipore, Billerica, MA, USA) and acquired by GBOX Chemi XT4 System (Syngene, Cambridge, UK). GeneTools software (Syngene) was used for quantification.
The data were expressed as mean ± standard deviation. Statistical analyses were carried out using one-way ANOVA, followed by Tukey's post-hoc test to assess the differences between the two groups. The data from qPCR, Western blot and pathological scores were compared using Kruskal–Wallis ANOVA test followed by Dunn's multiple comparison test. SPSS 18.0 was used for all statistical analyses. P <0.05 was considered statistically significant.
SNN reversed the changes in body and liver weights and serum lipid of the NASH model
Statistically significant differences were also observed in the blood lipid content. The serum levels of TG, TC, HDL-c, and LDL-c decreased in the model group (P <0.001), which were prevented by SNN intervention to a certain extent, particularly the levels of TC, HDL-c (P <0.01), and LDL-c (P <0.05) (Figure 1B).
SNN ameliorated hepatosteatosis induced by MCD diet
Liver histology evaluated by NAFLD Activity score
0 ± 0
2.6 ± 0.52***
0.75 ± 0.71#
Lobular inflammatory grade
0 ± 0
2.0 ± 0.76***
0. 5 ± 0.53#
0 ± 0
1.4 ± 0.92**
0. 6 ± 0.52
0 ± 0
4.8 ± 1.90***
1.9 ± 0.79#
SNN attenuated liver injury induced by MCD diet
SNN regulated hepatic oxidative stress in MCD diet-induced NASH
NASH progression is mediated by an inflammatory process in the liver with concomitant tissue damage. MCD diet-induced model is considered convenient for examining the role of OS and inflammation in the progression of NAFLD -. Choline and methionine are essential components for very-low-density lipoprotein (VLDL) and lipid oxidation. The deficiency of these components can reduce lipid oxidation and lipid transport outside of the hepatocytes, resulting in lipid accumulation in the liver. Choline and methionine deficiency also causes loss of active methyl which is important for glutathione cycle, leading to decreased antioxidants and promotion of OS ,. The mice fed with MCD diet lost weight because of reduced caloric intake, which is in contrast to humans with NASH who are mostly obese. Thus, differences exist between MCD dietary mouse model and human NASH . However, the MCD NASH model is one of the best established and commonly used dietary models for studying the evolution of inflammation and OS changes associated with NASH -. Liver injury and OS rapidly occur in MCD diet-fed model compared with other nutritional models. In particular, severe pericentral steatosis may develop in MCD diet-fed model after one week to two weeks; necro-inflammation may occur after two weeks; progressive pericellular and pericentral fibrosis may appear after eight weeks; and markedly enhanced OS can be observed from three weeks of MCD diet. Moreover, the liver injury induced by MCD diet is similar to human NASH ,,. In this study, MCD diet was used to feed C57BL/6 J mice for six weeks. Compared with the mice fed with control diet, hepatic steatosis appeared in the liver tissue accompanied with hepatocellular ballooning and scattered inflammatory cell infiltration, and transaminase activities were significantly increased in the MCD diet-fed mice, which indicate the establishment of the NASH model.
This study demonstrated the strong effect of SNN on preventing NASH development by simultaneously administering MCD diet to mice. The mice fed with MCD diet and administrated with SNN for six weeks exhibited only mild lipid deposition in their livers, instead of the prevalent hepatic steatosis, inflammation and hepatocellular ballooning degeneration that occurred in the NASH model without intervention. Consistently, the hepatocellular injury indicated by the increased serum levels of ALT, AST, bilirubin, and TNF-α and cell apoptosis in the model mice were evidently alleviated in the mice of the SNN group. Compared with our previous studies ,-, the current study elucidated that SNN not only ameliorated steatosis but also improved the more serious liver injury in NASH. In addition, SNN blocked the excessive loss of body and liver weights and decreased the circulating lipid, which occurred in the NASH models. This function is similar to preventing a body from progressing into an unhealthy status.
Our previous studies identified insulin resistance, leptin resistance, and upregulated free fatty acid (FFA) synthesis as parts of the mechanisms involved in the effect of SNN -. The model mice in the present study showed lower serum levels of insulin and leptin, as well as hepatic FFA synthetases, such as SREBP-1c and stearol-CoA desaturase 1, than those of the control mice (data not shown). By contrast, obviously increased levels of MDA and CYP2E1 were observed in the livers of the NASH mice induced by MCD diet, as reported in previous studies ,. Thus, the present study further focused on whether SNN could improve NASH through regulating OS.
OS is a disturbance between the pro-oxidant/antioxidant balance in favor of the former . As an etiological factor in NASH , OS can initiate hepatocellular injury and secondary recruitment of inflammation ,. Understanding the pathophysiological mechanisms of OS helps in the development of NASH treatment . MDA is a lipid oxidant that is widely used as a marker of lipid oxidation. MDA increased in 90% of NASH patients, illustrating the increase of OS ,,. Generation of lipid peroxides results in subsequent damage to hepatic membranes, proteins, and DNA. CYP2E1 is also regarded as a common marker of OS. CYP2E1 can oxidize a variety of small molecule substrate. Superoxide anion, a byproduct of the CYP2E1-mediated metabolism, is a very potent ROS, which may serve as part of the second hit to advance the severity of NAFLD to NASH ,. The results of this study showed increased CYP2E1 and MDA in the hepatic tissue of model mice, indicating the enhancement of OS. Nrf2 serves as a master regulator of a cellular defense system against OS. Upon exposure to ROS, Nrf2 dissociates and translocates into the nucleus, in which it binds to cis-acting antioxidant-responsive elements (ARE) and promotes the transcription of cytoprotective genes, such as NAD(P)H-quinone oxidoreductase (Nqo) and glutathione-S-transferase (Gst) . Increased expression of Nrf2 has been reported in mice fed with MCD diet for two weeks as an adaptive response to elevated ROS . However, in the present study, low levels of Nrf2 and its targeted genes, Nqo1 and Gstp1, were observed in the model mice. This result may be attributed to the exhaustion of compensatory mechanism for excess ROS after the mice were fed with MCD diet for six weeks. Previous study has found that livers of Nrf2 (-/-) mice on the MCD diet suffered more OS than their wild-type counterparts did . The consequences of OS include lipid peroxidation in cell membranes, stellate cell activation in the liver leading to liver fibrosis, chronic inflammation, and apoptosis ,. Moreover, ROS overproduction can promote hepatic insulin resistance, which further aggravates fatty liver . Increased CYP2E1 activity correlates with the degree of steatosis and level of the inflammatory cytokines (e.g., TNF-α) involved in the pathology of NASH . Thus, in the murine MCD diet-induced NASH model, hepatic injury develops as the decreased hepatocellular antioxidant defenses is overwhelmed by OS . The mice of the SNN group demonstrated lower levels of MDA and CYP2E1 than the mice fed with MCD diet but exhibited more expressions of Nrf2, Nqo1, and Gstp1. Thus, administratering SNN helped reverse the OS imbalance. This finding may be attributed to the integrated function of the natural components contained in SNN, such as protopanaxadiol, berberine, and resveratrol. These components are antioxidants that could directly scavenge free radicals or regulate the correlated factors ,-.
Apoptosis is a common mechanism of liver injury. The hepatocyte apoptosis assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) of liver biopsies and active caspases-3 and -7 significantly increases in patients with NASH and correlates with disease severity . The mitogen-activated protein kinase JNK signaling pathway contributes to stress-induced apoptosis. Previous studies demonstrated that sustained JNK activation occurs with the development of steatohepatitis, which can be activated by overexpression of CYP2E1 in NASH. The JNK pathway may be a link between OS and apoptosis ,. OS-associated JNK-mediated apoptosis requires the activation of the transcription factor c-Jun or induces apoptosis in a transcription-independent process by activating proapoptotic members of the Bcl-2 family, including Bim and Bax, or inactivating Bcl-2 and Bcl-xL ,. Consistently, this study observed that the activation of caspase-3 and JNK increased in the MCD diet-induced NASH model, together with low expression of Bcl-2. Such finding implies that JNK may mediate apoptosis by regulating Bcl-2. SNN treatment significantly increased the level of activated caspase-3 and JNK and downregulated Bcl-2, suggesting the function of SNN in the regulation of the pathway of OS–JNK apoptosis.
By administering SNN in the MCD diet-induced murine model, this study demonstrates that SNN has a beneficial effect on inhibiting hepatic steatosis and improving liver injury, including inflammation and hepatocyte apoptosis in NASH. The results of this study suggest the potential application of SNN in treating NAFLD with serious form of liver injury. However, these findings still require further validation by conducting clinical trials. SNN is a complex herbal medicine that may possess multiple pharmaceutical targets; however, in this study, the effect of regulating OS as well as subsequent anti-apoptosis and anti-inflammation functions were prominently observed to attenuate liver injury. Such functions contribute to explain the mechanism of SNN in modulating the pathophysiology of NASH. Furthermore, since OS and inflammation are also the major mechanism of alcoholic fatty liver disease ,,, SNN might also have potential for the treatment of this common liver disease.
SH designed the research. LY, WL, ZL and LD contributed to the animal experiments. LY, XH, SX and LY performed the biochemical and histopathological experiments. SH and LY analyzed the data and wrote the paper. JG conceived of the study and supervised the coordination. Co-first authors: LY and SH. All authors have read and approved the final manuscript.
This study was supported by the Innovation Program of shanghai Municipal Education Commission ( No.12ZZ119, No.E03008) shanghai, China; National Natural Science Foundation of China (No.81202667, No.81273727); Research Grant for Health Science and Technology of Pudong Health Bureau of Shanghai (PW2012A-40), China.
- Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G: A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010, 53: 372-384. 10.1016/j.jhep.2010.04.008.View ArticlePubMedGoogle Scholar
- Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011, 140: 124-131. 10.1053/j.gastro.2010.09.038.View ArticlePubMedGoogle Scholar
- Cohen JC, Horton JD, Hobbs HH: Human fatty liver disease: old questions and new insights. Science. 2011, 332: 1519-1523. 10.1126/science.1204265.PubMed CentralView ArticlePubMedGoogle Scholar
- Petta S, Muratore C, Craxi A: Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis. 2009, 41: 615-625. 10.1016/j.dld.2009.01.004.View ArticlePubMedGoogle Scholar
- Oliveira CP, da Costa Gayotto LC, Tatai C, Della Bina BI, Janiszewski M, Lima ES, Abdalla DS, Lopasso FP, Laurindo FR, Laudanna AA: Oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, in rats fed with a choline-deficient diet. J Cell Mol Med. 2002, 6: 399-406. 10.1111/j.1582-4934.2002.tb00518.x.View ArticlePubMedGoogle Scholar
- Aubert J, Begriche K, Knockaert L, Robin MA, Fromenty B: Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol. 2011, 35: 630-637. 10.1016/j.clinre.2011.04.015.View ArticlePubMedGoogle Scholar
- James O, Day C: Non-alcoholic steatohepatitis: another disease of affluence. Lancet. 1999, 353: 1634-1636. 10.1016/S0140-6736(99)00163-4.View ArticlePubMedGoogle Scholar
- Robertson G, Leclercq I, Farrell GC: Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001, 281: G1135-G1139.PubMedGoogle Scholar
- Niemela O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M: Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J Hepatol. 2000, 33: 893-901. 10.1016/S0168-8278(00)80120-8.View ArticlePubMedGoogle Scholar
- He J, Hu B, Shi X, Weidert ER, Lu P, Xu M, Huang M, Kelley EE, Xie W: Activation of the aryl hydrocarbon receptor sensitizes mice to nonalcoholic steatohepatitis by deactivating mitochondrial sirtuin deacetylase Sirt3. Mol Cell Biol. 2013, 33: 2047-2055. 10.1128/MCB.01658-12.PubMed CentralView ArticlePubMedGoogle Scholar
- Wanless IR, Shiota K: The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis. 2004, 24: 99-106. 10.1055/s-2004-823104.View ArticlePubMedGoogle Scholar
- Harrison SA, Kadakia S, Lang KA, Schenker S: Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol. 2002, 97: 2714-2724.PubMedGoogle Scholar
- Cortez-Pinto H, de Moura MC, Day CP: Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol. 2006, 44: 197-208. 10.1016/j.jhep.2005.09.002.View ArticlePubMedGoogle Scholar
- Dinarello CA: The IL-1 family and inflammatory diseases. Clin Exp Rheumatol. 2002, 20: S1-S13.PubMedGoogle Scholar
- Pober JS: Endothelial activation: intracellular signaling pathways. Arthritis Res. 2002, 4 (Suppl 3): S109-S116. 10.1186/ar576.PubMed CentralView ArticlePubMedGoogle Scholar
- Alisi A, Manco M, Devito R, Piemonte F, Nobili V: Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2010, 50: 645-649. 10.1097/MPG.0b013e3181c7bdf1.View ArticlePubMedGoogle Scholar
- Han YP, Tuan TL, Hughes M, Wu H, Garner WL: Transforming growth factor-beta - and tumor necrosis factor-alpha -mediated induction and proteolytic activation of MMP-9 in human skin. J Biol Chem. 2001, 276: 22341-22350. 10.1074/jbc.M010839200.PubMed CentralView ArticlePubMedGoogle Scholar
- Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L: Molecular mechanisms involved in NAFLD progression. J Mol Med. 2009, 87: 679-695. 10.1007/s00109-009-0464-1.View ArticlePubMedGoogle Scholar
- Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, Oshima M, Fujii C, Mukaida N: Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008, 118: 560-570.PubMed CentralPubMedGoogle Scholar
- Marcolin E, San-Miguel B, Vallejo D, Tieppo J, Marroni N, Gonzalez-Gallego J, Tunon MJ: Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. J Nutr. 2012, 142: 1821-1828. 10.3945/jn.112.165274.View ArticlePubMedGoogle Scholar
- Song HY, Zhang L, Pan JL, Yang LL, Ji G: Bioactivity of five components of Chinese herbal formula Jiangzhi granules against hepatocellular steatosis. J Integr Med. 2013, 11: 262-268. 10.3736/jintegrmed2013034.View ArticlePubMedGoogle Scholar
- Ma ZS, Liu T, Zheng PY, Xing LJ, Ji G: Effect of Chinese Medicine Jiangzhi Granula on Hepaticlipid of Nonalcoholic Fatty Liver Disease Rats. Chin Arch Tradit Chin Med. 2007, 25: 942-944.Google Scholar
- Pan J, Wang M, Song H, Wang L, Ji G: The efficacy and safety of traditional chinese medicine (jiang zhi granule) for nonalcoholic Fatty liver: a multicenter, randomized, placebo-controlled study. Evidence-based Complement Altern Med: eCAM. 2013, 2013: 965723-Google Scholar
- Zhang L, Liu T, Wang M, Xing LJ, Ji G, Zheng PY: Effect of Jiang zhi granula on leptin and leptin receptor of hypothalamus in rats with nonalcoholic liver disease. Chin J Integr Tradit West Med Liver Dis. 2009, 19: 88-91.Google Scholar
- Zheng PY, Zhang L, Liu T, Wang M, Xing LJ, Ji G: Effect of Jiangzhi granule on STAT3 expression in hypothalamus of rats with nonalcoholic fatty liver disease. World Chin J Digestol. 2009, 17: 753-757.Google Scholar
- Wang M, Sun S, Wu T, Zhang L, Song H, Hao W, Zheng P, Xing L, Ji G: Inhibition of LXRalpha/SREBP-1c-Mediated Hepatic Steatosis by Jiang-Zhi Granule. Evidence-based Complement Altern Med: eCAM. 2013, 2013: 584634-Google Scholar
- Zhang L, Xu J, Song H, Yao Z, Ji G: Extracts from Salvia-Nelumbinis naturalis alleviate hepatosteatosis via improving hepatic insulin sensitivity. J Transl Med. 2014, 12: 236-10.1186/s12967-014-0236-8.PubMed CentralView ArticlePubMedGoogle Scholar
- Lu YL, Wang M, Zhang L, He YQ, Yang L, Wang CH, Wang ZT, Ji G: Simultaneous determination of six components in the `Jiang-Zhi granule by UPLC-MS analysis. Chin J Nat Med. 2010, 8: 449-455.Google Scholar
- Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000, 105: 1067-1075. 10.1172/JCI8814.PubMed CentralView ArticlePubMedGoogle Scholar
- National Research Council (U.S.). Committee for the Update of the Guide for the Care and Use of Laboratory Animals., Institute for Laboratory Animal Research (U.S.), National Academies Press (U.S.): Guide for the care and use of laboratory animals. 8th edn. Washington, D.C.: National Academies Press; 2011.Google Scholar
- Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA, Network NCR: Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011, 53: 810-820. 10.1002/hep.24127.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang Y, Ausman LM, Russell RM, Greenberg AS, Wang XD: Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. J Nutr. 2008, 138: 1866-1871. 10.3945/jn.108.091009.PubMed CentralView ArticlePubMedGoogle Scholar
- Marcolin E, Forgiarini LF, Tieppo J, Dias AS, Freitas LA, Marroni NP: Methionine- and choline-deficient diet induces hepatic changes characteristic of non-alcoholic steatohepatitis. Arq Gastroenterol. 2011, 48: 72-79.PubMedGoogle Scholar
- Phung N, Pera N, Farrell G, Leclercq I, Hou JY, George J: Pro-oxidant-mediated hepatic fibrosis and effects of antioxidant intervention in murine dietary steatohepatitis. Int J Mol Med. 2009, 24: 171-180.PubMedGoogle Scholar
- George J, Pera N, Phung N, Leclercq I, Yun Hou J, Farrell G: Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol. 2003, 39: 756-764. 10.1016/S0168-8278(03)00376-3.View ArticlePubMedGoogle Scholar
- Fan JG, Qiao L: Commonly used animal models of non-alcoholic steatohepatitis. Hepatobiliary Pancreat Dis Int. 2009, 8: 233-240.PubMedGoogle Scholar
- Schattenberg JM, Galle PR: Animal models of non-alcoholic steatohepatitis: of mice and man. Dig Dis. 2010, 28: 247-254. 10.1159/000282097.View ArticlePubMedGoogle Scholar
- London RM, George J: Pathogenesis of NASH: animal models.Clinics in liver disease 2007, 11:55-74, viii.,Google Scholar
- Min AK, Kim MK, Kim HS, Seo HY, Lee KU, Kim JG, Park KG, Lee IK: Alpha-lipoic acid attenuates methionine choline deficient diet-induced steatohepatitis in C57BL/6 mice. Life Sci. 2012, 90: 200-205. 10.1016/j.lfs.2011.11.012.View ArticlePubMedGoogle Scholar
- Park HJ, Han JM, Kim HG, Choi MK, Lee JS, Lee HW, Son CG: Chunggan extract (CGX), methionine-and choline-deficient (MCD) diet-induced hepatosteatosis and oxidative stress in C57BL/6 mice. Hum Exp Toxicol. 2013, 32: 1258-1269. 10.1177/0960327113485253.View ArticlePubMedGoogle Scholar
- Sies H: Oxidative stress: from basic research to clinical application. Am J Med. 1991, 91: 31S-38S. 10.1016/0002-9343(91)90281-2.View ArticlePubMedGoogle Scholar
- Koruk M, Taysi S, Savas MC, Yilmaz O, Akcay F, Karakok M: Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann Clin Lab Sci. 2004, 34: 57-62.PubMedGoogle Scholar
- Koek GH, Liedorp PR, Bast A: The role of oxidative stress in non-alcoholic steatohepatitis.Clin Chim Acta 2011, 412:1297-1305.,Google Scholar
- Chalasani N, Deeg MA, Crabb DW: Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004, 99: 1497-1502. 10.1111/j.1572-0241.2004.30159.x.View ArticlePubMedGoogle Scholar
- Loguercio C, De Girolamo V, de Sio I, Tuccillo C, Ascione A, Baldi F, Budillon G, Cimino L, Di Carlo A, Di Marino MP, Morisco F, Picciotto F, Terracciano L, Vecchione R, Verde V, Del Vecchio Blanco C: Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol. 2001, 35: 568-574. 10.1016/S0168-8278(01)00192-1.View ArticlePubMedGoogle Scholar
- Lieber CS: CYP2E1: from ASH to NASH. Hepatology research: the official journal of the Japan Society of Hepatology. 2004, 28: 1-11. 10.1016/j.hepres.2003.08.001.View ArticleGoogle Scholar
- Abdelmegeed MA, Banerjee A, Yoo SH, Jang S, Gonzalez FJ, Song BJ: Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis. J Hepatol. 2012, 57: 860-866. 10.1016/j.jhep.2012.05.019.PubMed CentralView ArticlePubMedGoogle Scholar
- Gong P, Cederbaum AI: Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1. Hepatology. 2006, 43: 144-153. 10.1002/hep.21004.View ArticlePubMedGoogle Scholar
- Zhang YK, Yeager RL, Tanaka Y, Klaassen CD: Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. Toxicol Appl Pharmacol. 2010, 245: 326-334. 10.1016/j.taap.2010.03.016.PubMed CentralView ArticlePubMedGoogle Scholar
- Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, Dillon JF, Ashford ML, Hayes JD: Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med. 2010, 48: 357-371. 10.1016/j.freeradbiomed.2009.11.007.View ArticlePubMedGoogle Scholar
- Orsu P, Murthy BV, Akula A: Cerebroprotective potential of resveratrol through anti-oxidant and anti-inflammatory mechanisms in rats. J Neural Transm. 2013, 120: 1217-1223. 10.1007/s00702-013-0982-4.View ArticlePubMedGoogle Scholar
- Moghaddam HK, Baluchnejadmojarad T, Roghani M, Khaksari M, Norouzi P, Ahooie M, Mahboobi F: Berberine ameliorate oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats. Mol Neurobiol. 2014, 49: 820-826. 10.1007/s12035-013-8559-7.View ArticlePubMedGoogle Scholar
- Domitrovic R, Jakovac H, Marchesi VV, Blazekovic B: Resolution of liver fibrosis by isoquinoline alkaloid berberine in CCl(4)-intoxicated mice is mediated by suppression of oxidative stress and upregulation of MMP-2 expression. J Med Food. 2013, 16: 518-528. 10.1089/jmf.2012.0175.PubMed CentralView ArticlePubMedGoogle Scholar
- Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 2003, 125: 437-443. 10.1016/S0016-5085(03)00907-7.View ArticlePubMedGoogle Scholar
- Schattenberg JM, Singh R, Wang Y, Lefkowitch JH, Rigoli RM, Scherer PE, Czaja MJ: JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology. 2006, 43: 163-172. 10.1002/hep.20999.View ArticlePubMedGoogle Scholar
- Yamamoto K, Ichijo H, Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol. 1999, 19: 8469-8478.PubMed CentralView ArticlePubMedGoogle Scholar
- Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001, 292: 727-730. 10.1126/science.1059108.PubMed CentralView ArticlePubMedGoogle Scholar
- Miranda-Mendez A, Lugo-Baruqui A, Armendariz-Borunda J: Molecular basis and current treatment for alcoholic liver disease. Int J Environ Res Public Health. 2010, 7: 1872-1888. 10.3390/ijerph7051872.PubMed CentralView ArticlePubMedGoogle Scholar
- Day CP: Treatment of alcoholic liver disease. Liver Transpl. 2007, 13: S69-S75. 10.1002/lt.21336.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.